Jump to content

Apixaban: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
No edit summary
 
(14 intermediate revisions by 9 users not shown)
Line 1: Line 1:
{{Short description|Anticoagulant medication}}
{{Short description|Anticoagulant medication}}
{{Use dmy dates|date=September 2023}}
{{Use dmy dates|date=August 2024}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
{{Infobox drug
Line 103: Line 103:


<!-- Definition and medical uses -->
<!-- Definition and medical uses -->
'''Apixaban''', sold under the brand name '''Eliquis''', is an [[anticoagulant]] medication used to treat and prevent [[venous thromboembolism|blood clots]] and to prevent [[stroke]] in people with nonvalvular [[atrial fibrillation]] through directly inhibiting [[factor Xa#Factor Xa|factor Xa]].<ref name="AHFS2019" /><ref name="BNF76">{{cite book|title=British national formulary: BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=124–125|edition=76}}</ref><ref name="FDA generics">{{cite web|date=23 December 2019|title=FDA approves first generics of Eliquis|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis|url-status=live|archive-url=https://web.archive.org/web/20191223220042/https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis|archive-date=23 December 2019|access-date=23 December 2019|website=U.S. [[Food and Drug Administration]] (FDA)}} {{PD-notice}}</ref> Specifically, it is used to prevent blood clots following [[hip replacement|hip]] or [[knee replacement]] and in those with a history of prior clots.<ref name="AHFS2019" /><ref name="FDA generics" /> It is used as an alternative to [[warfarin]] and does not require monitoring by blood tests<ref name="AHFS2019" /> or dietary restrictions.<ref>{{cite magazine | vauthors = Hall H |author-link=Harriet Hall |date=September-October 2020 |title=How a Drug Is Born |url= |magazine=[[Skeptical Inquirer]] |location=Amherst, New York |publisher=[[Center for Inquiry]] |access-date=}}</ref> It is taken [[Oral administration|by mouth]].<ref name=AHFS2019/>
'''Apixaban''', sold under the brand name '''Eliquis''', is an [[anticoagulant]] medication used to treat and prevent [[venous thromboembolism|blood clots]] and to prevent [[stroke]] in people with nonvalvular [[atrial fibrillation]] through directly inhibiting [[factor Xa#Factor Xa|factor Xa]].<ref name="AHFS2019" /><ref name="BNF76">{{cite book|title=British national formulary: BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=124–125|edition=76}}</ref><ref name="FDA generics">{{cite web|date=23 December 2019|title=FDA approves first generics of Eliquis|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis|url-status=live|archive-url=https://web.archive.org/web/20191223220042/https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis|archive-date=23 December 2019|access-date=23 December 2019|website=U.S. [[Food and Drug Administration]] (FDA)}} {{PD-notice}}</ref> It is used as an alternative to [[warfarin]] to prevent blood clots following [[hip replacement|hip]] or [[knee replacement]] and in those with a history of prior clots.<ref name="AHFS2019" /><ref name="FDA generics" /> and does not require monitoring by blood tests<ref name="AHFS2019" /> or dietary restrictions.<ref>{{cite magazine | author1= Hall H |author-link=Harriet Hall |date=September-October 2020 |title=How a Drug Is Born |url= |magazine=[[Skeptical Inquirer]] |location=Amherst, New York |publisher=[[Center for Inquiry]] |access-date=}}</ref> It is taken [[Oral administration|by mouth]].<ref name=AHFS2019/>


<!-- Side effects and mechanism -->
<!-- Side effects and mechanism -->
Line 109: Line 109:


<!-- Society and culture -->
<!-- Society and culture -->
In 2007, [[Pfizer]] and [[Bristol Myers Squibb|Bristol-Myers Squibb]] began development of apixaban as an anticoagulant.<ref>{{cite press release|title=Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds|url=https://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_worldwide_collaboration_to_develop_and_commercialize_anticoagulant_and_metabolic_compounds|url-status=live|access-date=25 December 2021|website=Pfizer |archive-url=https://web.archive.org/web/20150910142120/http://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_worldwide_collaboration_to_develop_and_commercialize_anticoagulant_and_metabolic_compounds |archive-date=10 September 2015 }}</ref> Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.<ref name="Eliquis EPAR">{{cite web | title=Eliquis EPAR | website=[[European Medicines Agency]] | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis | access-date=22 April 2020}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name=AHFS2019>{{cite web |title=Apixaban Monograph for Professionals |url=https://www.drugs.com/monograph/apixaban.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=27 March 2019 }}</ref><ref name="FDA approval">{{cite web|date=13 February 2013|title=Drug Approval Package: Eliquis (apixaban) NDA #202155|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm|access-date=23 December 2019|publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO22nd">{{cite book | vauthors = ((World Health Organization)) | title = World Health Organization model list of essential medicines: 22nd list (2021) | year = 2021 | hdl = 10665/345533 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2021.02 | hdl-access=free }}</ref> In 2021, it was the 33rd most commonly prescribed medication in the United States with more than 17{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2021 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=14 January 2024 | archive-date=15 January 2024 | archive-url=https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title=Apixaban - Drug Usage Statistics | website=ClinCalc | url=https://clincalc.com/DrugStats/Drugs/Apixaban | access-date=14 January 2024}}</ref> It is available as a generic medication, although not in the United States.<ref name="FDA generics" /><ref name="with-court-win-bms-and-pfizer">{{cite web|title=With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now|url=https://www.biospace.com/article/with-court-win-bms-and-pfizer-stave-off-generic-challengers-to-eliquis-for-now/|access-date=29 November 2021|website=BioSpace}}</ref>
In 2007, [[Pfizer]] and [[Bristol Myers Squibb|Bristol-Myers Squibb]] began the development of apixaban as an anticoagulant.<ref>{{cite press release|title=Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds|url=https://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_worldwide_collaboration_to_develop_and_commercialize_anticoagulant_and_metabolic_compounds|url-status=live|access-date=25 December 2021|website=Pfizer |archive-url=https://web.archive.org/web/20150910142120/http://www.pfizer.com/news/press-release/press-release-detail/bristol_myers_squibb_and_pfizer_announce_worldwide_collaboration_to_develop_and_commercialize_anticoagulant_and_metabolic_compounds |archive-date=10 September 2015 }}</ref> Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.<ref name="Eliquis EPAR">{{cite web | title=Eliquis EPAR | website=[[European Medicines Agency]] | date=17 September 2018 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis | access-date=22 April 2020}} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref><ref name=AHFS2019>{{cite web |title=Apixaban Monograph for Professionals |url=https://www.drugs.com/monograph/apixaban.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=27 March 2019 }}</ref><ref name="FDA approval">{{cite web|date=13 February 2013|title=Drug Approval Package: Eliquis (apixaban) NDA #202155|url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000TOC.cfm|access-date=23 December 2019|publisher=U.S. [[Food and Drug Administration]] (FDA)}}</ref> It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref> In 2022, it was the 27th most commonly prescribed medication in the United States, with more than 19{{nbsp}}million prescriptions.<ref>{{cite web | title=The Top 300 of 2022 | url=https://clincalc.com/DrugStats/Top300Drugs.aspx | website=ClinCalc | access-date=30 August 2024 | archive-date=30 August 2024 | archive-url=https://web.archive.org/web/20240830202410/https://clincalc.com/DrugStats/Top300Drugs.aspx | url-status=live }}</ref><ref>{{cite web | title = Apixaban Drug Usage Statistics, United States, 2013 - 2022 | website = ClinCalc | url = https://clincalc.com/DrugStats/Drugs/Apixaban | access-date = 30 August 2024 }}</ref> It is available as a generic medication, although not in the United States.<ref name="FDA generics" /><ref name="with-court-win-bms-and-pfizer">{{cite web|title=With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now|url=https://www.biospace.com/article/with-court-win-bms-and-pfizer-stave-off-generic-challengers-to-eliquis-for-now/|access-date=29 November 2021|website=BioSpace|date=6 August 2020 }}</ref>


==Medical uses==
==Medical uses==
Line 142: Line 142:
Apixaban was approved for medical use in the European Union in May 2011.<ref name="Eliquis EPAR" />
Apixaban was approved for medical use in the European Union in May 2011.<ref name="Eliquis EPAR" />


A [[new drug application]] (NDA) for the approval of apixaban was submitted to the U.S. [[Food and Drug Administration]] (FDA) by [[Bristol-Myers Squibb]] (BMS) and [[Pfizer]] jointly after conclusion of the ARISTOTLE clinical trial in 2011.<ref>{{cite journal | vauthors = Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L | title = Apixaban versus warfarin in patients with atrial fibrillation | journal = The New England Journal of Medicine | volume = 365 | issue = 11 | pages = 981–992 | date = September 2011 | pmid = 21870978 | doi = 10.1056/NEJMoa1107039 | s2cid = 43262809 | doi-access = free }}</ref><ref name="FDA approval" /> Apixaban was approved for the prevention of stroke in people with atrial fibrillation on 28 December 2012.<ref name="FDA approval" /><ref name="Cada">{{cite journal | vauthors = Cada DJ, Levien TL, Baker DE | title = Apixaban | journal = Hospital Pharmacy | volume = 48 | issue = 6 | pages = 494–509 | date = June 2013 | pmid = 24421512 | pmc = 3839491 | doi = 10.1310/hpj4806-494 }}</ref> On 13 March 2014, it was approved for the additional indication of preventing [[deep vein thrombosis]] and [[pulmonary embolism]] in people who have recently undergone knee or hip replacement.<ref name="FDA letters">{{cite web|title=FDA-Approved Drugs: Eliquis (apixaban)|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202155|access-date=23 December 2019|website=U.S. [[Food and Drug Administration]] (FDA)}}</ref><ref>{{cite news| vauthors = Neale T |date=14 March 2014|title=FDA OKs Apixaban for DVT Prevention|agency=MedPage Today|url=http://www.medpagetoday.com/Cardiology/VenousThrombosis/44776|access-date=17 September 2015}}</ref> On 21 August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism.<ref name="FDA letters" /><ref name="pfizer1">{{cite press release|title=U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy|url=http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy|publisher=Pfizer|date=21 August 2014|access-date=26 February 2016}}</ref> During its development the drug was known as BMS-562247-01.<ref name="pubchem">{{cite web|title=Apixaban|url=https://pubchem.ncbi.nlm.nih.gov/compound/Apixaban|access-date=2 September 2022|publisher=PubChem, US National Library of Medicine|date=27 August 2022}}</ref> By late 2019, sales of the product by BMS accounted for thirty-percent of their quarterly revenue.<ref name=":0">{{cite news|date=24 December 2019|title=FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis|work=Business Medical Dialogues|publisher=Minerva Medical Treatment|location=New Delhi, India|url=https://business.medicaldialogues.in/first-mylan-micro-labs-get-usfda-nod-for-generic-version-of-blood-thinner-eliquis/|access-date=24 December 2019}}</ref>
A [[new drug application]] (NDA) for the approval of apixaban was submitted to the US [[Food and Drug Administration]] (FDA) by [[Bristol-Myers Squibb]] (BMS) and [[Pfizer]] jointly after the conclusion of the ARISTOTLE clinical trial in 2011.<ref>{{cite journal | vauthors = Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L | title = Apixaban versus warfarin in patients with atrial fibrillation | journal = The New England Journal of Medicine | volume = 365 | issue = 11 | pages = 981–992 | date = September 2011 | pmid = 21870978 | doi = 10.1056/NEJMoa1107039 | s2cid = 43262809 | doi-access = free }}</ref><ref name="FDA approval" /> Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012.<ref name="FDA approval" /><ref name="Cada">{{cite journal | vauthors = Cada DJ, Levien TL, Baker DE | title = Apixaban | journal = Hospital Pharmacy | volume = 48 | issue = 6 | pages = 494–509 | date = June 2013 | pmid = 24421512 | pmc = 3839491 | doi = 10.1310/hpj4806-494 }}</ref> In March 2014, it was approved for the additional indication of preventing [[deep vein thrombosis]] and [[pulmonary embolism]] in people who have recently undergone knee or hip replacement.<ref name="FDA letters">{{cite web|title=FDA-Approved Drugs: Eliquis (apixaban)|url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202155|access-date=23 December 2019|website=U.S. [[Food and Drug Administration]] (FDA)}}</ref><ref>{{cite news| vauthors = Neale T |date=14 March 2014|title=FDA OKs Apixaban for DVT Prevention|agency=MedPage Today|url=http://www.medpagetoday.com/Cardiology/VenousThrombosis/44776|access-date=17 September 2015}}</ref> In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism.<ref name="FDA letters" /><ref name="pfizer1">{{cite press release|title=U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy|url=http://www.pfizer.com/news/press-release/press-release-detail/u_s_fda_approves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombosis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_the_risk_of_recurrent_dvt_and_pe_following_initial_therapy|publisher=Pfizer|date=21 August 2014|access-date=26 February 2016}}</ref> During its development the drug was known as BMS-562247-01.<ref name="pubchem">{{cite web|title=Apixaban|url=https://pubchem.ncbi.nlm.nih.gov/compound/Apixaban|access-date=2 September 2022|publisher=PubChem, US National Library of Medicine|date=27 August 2022}}</ref> By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.<ref name=":0">{{cite news|date=24 December 2019|title=FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis|work=Business Medical Dialogues|publisher=Minerva Medical Treatment|location=New Delhi, India|url=https://business.medicaldialogues.in/first-mylan-micro-labs-get-usfda-nod-for-generic-version-of-blood-thinner-eliquis/|access-date=24 December 2019}}</ref>


== Society and culture ==
== Society and culture ==
Line 150: Line 150:
In July 2022, the Canadian generic drug company, [[Apotex Inc.]], obtained approval for marketing of apixaban.<ref name="apotex">{{cite web | vauthors = Levy S |title=Apotex offers generic Eliquis in Canada |url=https://drugstorenews.com/apotex-offers-generic-eliquis-canada |publisher=Drugstore News |access-date=2 September 2022 |date=1 August 2022}}</ref><ref>{{cite press release | title=First Generic Alternative to Eliquis Now Available in Canada | website=Apotex | date=20 July 2022 | url=https://www.apotex.com/global/about-us/press-center/2022/07/20/first-generic-alternative-to-eliquis-now-available-in-canada | access-date=29 June 2023}}</ref>
In July 2022, the Canadian generic drug company, [[Apotex Inc.]], obtained approval for marketing of apixaban.<ref name="apotex">{{cite web | vauthors = Levy S |title=Apotex offers generic Eliquis in Canada |url=https://drugstorenews.com/apotex-offers-generic-eliquis-canada |publisher=Drugstore News |access-date=2 September 2022 |date=1 August 2022}}</ref><ref>{{cite press release | title=First Generic Alternative to Eliquis Now Available in Canada | website=Apotex | date=20 July 2022 | url=https://www.apotex.com/global/about-us/press-center/2022/07/20/first-generic-alternative-to-eliquis-now-available-in-canada | access-date=29 June 2023}}</ref>


Pfizer reported revenue of {{US$|6.747 billion}} for Eliquis in 2023.<ref>{{cite web | title=Pfizer’s year in review | website=Pfizer 2023 Annual Report | date=31 December 2023 | url=https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2023/ | access-date=30 December 2024}}</ref>
Apixaban is one of the ten medications proposed for price negotiations in the US under the [[Inflation Reduction Act]]. According to Bristol Myers Squibb the average pay per month per patient for Eliquis is {{US$|55}}.<ref>{{cite web |last=Kansteiner |first=Fraiser |date=29 August 2023 |title=Drugs from J&J, Merck, Novartis, BMS and more set for first round of Medicare price negotiations: CMS |url=https://www.fiercepharma.com/pharma/medicare-unveils-list-10-drugs-set-price-negotiations-under-ira |access-date=31 August 2023}}</ref>

Apixaban is one of ten medications covered by price negotiations in the US under the [[Inflation Reduction Act]]. The negotiations, conducted by the [[Centers for Medicare & Medicaid Services]], apply to pricing for [[Medicare (United States)|Medicare]] recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521.<ref>{{cite web | title=Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 | website=CMS | date=15 August 2024 | url=https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026 | access-date=30 December 2024}}</ref> The pricing is set to take effect in 2026.<ref>{{Cite web |last=Lovelace Jr. |first=Berkeley |date=15 August 2024 |title=Medicare announces lower prices on 10 common, high-cost drugs |url=https://www.nbcnews.com/health/health-news/medicare-cost-lower-medication-diabetes-blood-thinners-rcna166385 |access-date=21 August 2024 |website=NBC News }}</ref><ref>{{Cite web |date=15 August 2024 |title=Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices |url=https://aspe.hhs.gov/sites/default/files/documents/3e8abec86039ac0ed674a8c5fac492e3/price-change-over-time-brief.pdf |publisher=Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services }}</ref>


==References==
==References==
Line 157: Line 159:
{{Antithrombotics}}
{{Antithrombotics}}
{{Portal bar | Medicine}}
{{Portal bar | Medicine}}
{{Authority control}}


[[Category:Drugs developed by Bristol Myers Squibb]]
[[Category:Drugs developed by Bristol Myers Squibb]]
Line 162: Line 165:
[[Category:Delta-lactams]]
[[Category:Delta-lactams]]
[[Category:Drugs developed by Pfizer]]
[[Category:Drugs developed by Pfizer]]
[[Category:Phenol ethers]]
[[Category:4-Methoxyphenyl compounds]]
[[Category:2-Piperidinones]]
[[Category:2-Piperidinones]]
[[Category:Pyrazolopyridines]]
[[Category:Pyrazolopyridines]]
[[Category:World Health Organization essential medicines]]
[[Category:Wikipedia medicine articles ready to translate]]
[[Category:Wikipedia medicine articles ready to translate]]

Latest revision as of 05:02, 30 December 2024

Apixaban
Clinical data
Trade namesEliquis, others
Other namesBMS-562247-01
AHFS/Drugs.comMonograph
MedlinePlusa613032
License data
Pregnancy
category
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability~50%
Protein binding~87%
MetabolismCYP3A4, CYP3A5, CYP1A2 and others
Elimination half-life9–14 h
ExcretionBile duct (75%), kidney (25%)
Identifiers
  • 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.167.332 Edit this at Wikidata
Chemical and physical data
FormulaC25H25N5O4
Molar mass459.506 g·mol−1
3D model (JSmol)
  • O=C5N(c4ccc(N3C(=O)c1c(c(nn1c2ccc(OC)cc2)C(=O)N)CC3)cc4)CCCC5
  • InChI=1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32) checkY
  • Key:QNZCBYKSOIHPEH-UHFFFAOYSA-N checkY
  (verify)

Apixaban, sold under the brand name Eliquis, is an anticoagulant medication used to treat and prevent blood clots and to prevent stroke in people with nonvalvular atrial fibrillation through directly inhibiting factor Xa.[6][7][8] It is used as an alternative to warfarin to prevent blood clots following hip or knee replacement and in those with a history of prior clots.[6][8] and does not require monitoring by blood tests[6] or dietary restrictions.[9] It is taken by mouth.[6]

Common side effects include bleeding and nausea.[6][7] Other side effects may include bleeding around the spine and allergic reactions.[6] Use is not recommended during pregnancy or breastfeeding.[1][7] Use appears to be relatively safe in those with mild kidney problems.[7] Compared to warfarin it has fewer interactions with other medications.[10] It is a direct factor Xa inhibitor.[6]

In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant.[11] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.[5][6][12] It is on the World Health Organization's List of Essential Medicines.[13] In 2022, it was the 27th most commonly prescribed medication in the United States, with more than 19 million prescriptions.[14][15] It is available as a generic medication, although not in the United States.[8][16]

Medical uses

[edit]

Apixaban is indicated for the following:[4]

In the EU, apixaban is indicated for the prevention of venous thromboembolic events (VTE) in adults who have undergone elective hip or knee replacement surgery, the prevention of stroke and systemic embolism in adults with non-valvular atrial fibrillation (NVAF) with one or more risk factors, for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and for the prevention of recurrent DVT and PE in adults.[5]

Atrial fibrillation

[edit]

Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.[17]

Apixaban and other anticoagulants (dabigatran, edoxaban and rivaroxaban) appear equally effective as warfarin in preventing non-hemorrhagic stroke in people with atrial fibrillation and are associated with lower risk of intracranial bleeding.[18][19]

While apixaban may be used in people with severely decreased kidney function and those on hemodialysis it has not been studied in these groups.[6]

Side effects

[edit]

Bleeding

[edit]

Apixaban can increase the risk of bleeding which may be serious and potentially fatal. Concurrent use with other medications that affect blood clotting can further increase this risk. This includes medications such as other anticoagulants, heparin, aspirin, antiplatelet medications, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs).[4][20][21][22]

Andexanet alfa is a US Food and Drug Administration (FDA) approved antidote for apixaban in people with uncontrolled and life-threatening bleeding events.[23][24]

Spinal puncture

[edit]

Following spinal anesthesia or puncture, people who are being treated with anti-thrombotic agents are at higher risk for developing a hematoma, which causes long-term or permanent paralysis. The risk of this may be increased by using epidural or intrathecal catheters after a surgical operation or from the concurrent use of medicinal agents that affect hemostasis.[4]

Mechanism of action

[edit]

Apixaban is a highly selective, orally bioavailable, and reversible direct inhibitor of free and clot-bound factor Xa. Factor Xa catalyzes the conversion of prothrombin to thrombin, the final enzyme in the coagulation cascade that is responsible for fibrin clot formation.[25] Apixaban has no direct effect on platelet aggregation, but by inhibiting factor Xa, it indirectly decreases clot formation induced by thrombin.[4]

History

[edit]

Apixaban was approved for medical use in the European Union in May 2011.[5]

A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011.[26][12] Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012.[12][27] In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement.[28][29] In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism.[28][30] During its development the drug was known as BMS-562247-01.[31] By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.[32]

Society and culture

[edit]

Economics

[edit]

In December 2019, the US FDA approved a generic version of apixaban produced jointly by Mylan and Micro Labs.[33][32][8] BMS and Pfizer worked quickly to block generics from being created, and in August 2020, they won a patent infringement lawsuit against Sigmapharm, Sunshine Lake, and Unichem, after previously settling patent cases against 25 other companies.[34][35] In September 2021, a Federal Circuit Court upheld the ruling.[36] The result is that apixaban generics will most likely not be available in the United States until at least 2026, but possibly 2031.[16]

In July 2022, the Canadian generic drug company, Apotex Inc., obtained approval for marketing of apixaban.[37][38]

Pfizer reported revenue of US$6.747 billion for Eliquis in 2023.[39]

Apixaban is one of ten medications covered by price negotiations in the US under the Inflation Reduction Act. The negotiations, conducted by the Centers for Medicare & Medicaid Services, apply to pricing for Medicare recipients. The results of the negotiations were announced in August 2024, and Medicare's negotiated price for a 30-day supply of Eliquis is $231, a 56% decrease from the 2023 list price of $521.[40] The pricing is set to take effect in 2026.[41][42]

References

[edit]
  1. ^ a b "Apixaban (Eliquis) Use During Pregnancy". Drugs.com. 21 June 2019. Retrieved 13 August 2020.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 3 May 2022. Retrieved 8 October 2022.
  4. ^ a b c d e "Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit". DailyMed. 26 November 2019. Retrieved 22 April 2020.
  5. ^ a b c d "Eliquis EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  6. ^ a b c d e f g h i "Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.
  7. ^ a b c d British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 124–125. ISBN 9780857113382.
  8. ^ a b c d "FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. Public Domain This article incorporates text from this source, which is in the public domain.
  9. ^ Hall H (September–October 2020). "How a Drug Is Born". Skeptical Inquirer. Amherst, New York: Center for Inquiry.
  10. ^ Kiser K (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 9783319546438.
  11. ^ "Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds". Pfizer (Press release). Archived from the original on 10 September 2015. Retrieved 25 December 2021.
  12. ^ a b c "Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Retrieved 23 December 2019.
  13. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  14. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  15. ^ "Apixaban Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  16. ^ a b "With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now". BioSpace. 6 August 2020. Retrieved 29 November 2021.
  17. ^ "Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation" (PDF). National Institute for Health and Care Excellence. January 2013. Retrieved 26 February 2016.
  18. ^ Gómez-Outes A, Terleira-Fernández AI, Calvo-Rojas G, Suárez-Gea ML, Vargas-Castrillón E (2013). "Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups". Thrombosis. 2013: 640723. doi:10.1155/2013/640723. PMC 3885278. PMID 24455237.
  19. ^ Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
  20. ^ "Atrial fibrillation and new oral anticoagulant drugs". U.S. Food and Drug Administration (FDA). 2 December 2015. Retrieved 22 April 2020.
  21. ^ "Atrial fibrillation, oral anticoagulant drugs, and their reversal agents". U.S. Food and Drug Administration. 2 December 2015. Retrieved 22 April 2020.
  22. ^ "No change is needed in use of direct oral anticoagulants following EMA-funded study". European Medicines Agency (EMA). 27 March 2020. Retrieved 22 April 2020.
  23. ^ "Andexxa- andexanet alfa injection, powder, lyophilized, for solution". DailyMed. 8 January 2019. Retrieved 23 December 2019.
  24. ^ "Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)". U.S. Food and Drug Administration (FDA). 31 December 2018. Retrieved 22 April 2020.
  25. ^ Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
  26. ^ Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.
  27. ^ Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.
  28. ^ a b "FDA-Approved Drugs: Eliquis (apixaban)". U.S. Food and Drug Administration (FDA). Retrieved 23 December 2019.
  29. ^ Neale T (14 March 2014). "FDA OKs Apixaban for DVT Prevention". MedPage Today. Retrieved 17 September 2015.
  30. ^ "U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy" (Press release). Pfizer. 21 August 2014. Retrieved 26 February 2016.
  31. ^ "Apixaban". PubChem, US National Library of Medicine. 27 August 2022. Retrieved 2 September 2022.
  32. ^ a b "FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis". Business Medical Dialogues. New Delhi, India: Minerva Medical Treatment. 24 December 2019. Retrieved 24 December 2019.
  33. ^ "2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  34. ^ "Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc". JD Supra. Retrieved 30 November 2021.
  35. ^ "Bristol Myers, Pfizer fend off a key challenge to their top-selling heart drug". BioPharma Dive. Retrieved 30 November 2021.
  36. ^ "Federal Circuit Crystallizes BMS' Apixaban District Court Win". The National Law Review. Retrieved 30 November 2021.
  37. ^ Levy S (1 August 2022). "Apotex offers generic Eliquis in Canada". Drugstore News. Retrieved 2 September 2022.
  38. ^ "First Generic Alternative to Eliquis Now Available in Canada". Apotex (Press release). 20 July 2022. Retrieved 29 June 2023.
  39. ^ "Pfizer's year in review". Pfizer 2023 Annual Report. 31 December 2023. Retrieved 30 December 2024.
  40. ^ "Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026". CMS. 15 August 2024. Retrieved 30 December 2024.
  41. ^ Lovelace Jr B (15 August 2024). "Medicare announces lower prices on 10 common, high-cost drugs". NBC News. Retrieved 21 August 2024.
  42. ^ "Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices" (PDF). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 15 August 2024.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Apixaban&oldid=1266117009"